KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Notes Payables: 2020-2023

Historic Notes Payables for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Dec 2023 value amounting to $41.4 million.

  • Amneal Pharmaceuticals' Notes Payables was N/A to $41.9 million in Q1 2024 from the same period last year, while for Mar 2024 it was $41.9 million, marking a year-over-year change of. This contributed to the annual value of $41.4 million for FY2023, which is 4.38% up from last year.
  • As of FY2023, Amneal Pharmaceuticals' Notes Payables stood at $41.4 million, which was up 4.38% from $39.7 million recorded in FY2022.
  • Amneal Pharmaceuticals' 5-year Notes Payables high stood at $41.4 million for FY2023, and its period low was $1.0 million during FY2020.
  • In the last 2 years, Amneal Pharmaceuticals' Notes Payables had a median value of $40.6 million in 2022 and averaged $40.6 million.
  • Data for Amneal Pharmaceuticals' Notes Payables shows a peak YoY increased of 4.38% (in 2023) over the last 5 years.
  • Amneal Pharmaceuticals' Notes Payables (Yearly) stood at $1.0 million in 2020, then reached $39.7 million in 2022, then grew by 4.38% to $41.4 million in 2023.